CClinicalTrials.gg
Status unknownNCT04819074PRAEMIUMUpdated Dec 21, 2021

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

An observational study in Aneurysm, Brain, sponsored by University of Zurich. Status unknown at 37 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-21.

Sponsored by University of Zurich · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Study summary

Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically applicable, robust ML-based prediction tool based on multicenter data from a range of international centers.

Read the detailed description

Introduction Unruptured intracranial aneurysms (UIAs) are incidentally detected at an increasing rate, mostly owing to the rise in availability of non-invasive cranial imaging. Decision-making in UIAs is complex and requires consideration of many risk factors for aneurysm growth and rupture to balance the benefits and risks of treatment versus observation. This is due to: 1) the high morbidity and case fatality inherent to aneurysmal subarachnoid hemorrhage (SAH) 2) the relatively low rupture rate of unruptured aneurysms; 3) the potential morbidity and mortality rate associated with either microsurgical or endovascular treatment.

Some consistent risk factors for rupture have been identified, including involvement of the posterior circulation, larger diameter, higher age, and some specific populations such as Japanese and Finnish patients. Many other risk factors have been suggested based on varying levels of evidence. However, it is difficult to integrate this considerable number of factors into a single risk assessment and to present a clear clinical decision making algorithm to patients. A range of scoring systems have been developed and validated to approximate the risk of rupture (PHASES) and growth (ELAPSS) or to balance the risks and benefits of microsurgical treatment versus follow-up imaging directly (UIATS) by integrating some of these risk factors. Still, these scores are focused on predicting rupture events instead of neurological outcome. In addition, they usually are focused on solely one outcome, instead of providing a wide range of objective predictive analytics that may then improve shared decision-making.

Machine learning (ML) methods have been extraordinarily effective at integrating many clinical patient variables into one holistic risk prediction tailored to each patient. A previous pilot study has been carried out to assess the feasibility of predicting surgical outcomes after surgery for UIAs in a small single-center sample, and it was found that prediction was feasible with good performance metrics, and the most important factors to be included in such models were also identified. A robust, multicenter, externally validated prediction model or predictive score for surgical outcome after microsurgery for UIAs does not yet exist.

Methods Data will be collected by a range of international centers. Overall, the model will be built and publication will be compiled according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines.

Each center will collect their data either retrospectively, or from a prospective registry, or from a prospective registry supplemented by retrospectively collected variables. Data from patients operated from January 1st 2010 and onwards will be eligible for inclusion. Data collection should be completed, and deidentified data should be sent to the sponsor institution.

A standardized Excel spreadsheet will be provided by the sponsor. The data will be entered in standardized and anonymized form. This spreadsheet will only contain a study-specific patient number. The data set is anonymized source data that includes clinical data extracted from electronic health records (retrospectively or from a prospective registry of already existing data). The data will be anonymized upon entering them into the PRAEMIUM Excel spreadsheet, after which the patients will be numbered consecutively and there will be no way to trace the data back to individual patients. No identifiable data such as date of birth will be included. Whenever the PRAEMIUM Excel spreadsheet is transferred, it will be encrypted using a password and sent through a secure institutional e-mail server. The password will be sent in a separate e-mail. Some missing data is acceptable, but should be kept to a minimum (i.e. must be \< 10%)

Endpoint Definitions Models will be developed for the following three endpoints at discharge: Poor neurological outcome (1), as well as presence of (2) new sensorimotor neurological deficits and (3) any complications (surgical or non-surgical). Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0.The Clavien-Dindo grading system is a classification of surgical complications: Grad 0 signifying no complication, Grade I identifying complications with any deviation from the normal intra- or postoperative course requiring medical treatment, and so forth. Detailed definitions are provided in the Excel spreadsheet. Surgery-related as well as none-surgery-related complications are counted. In case of multiple complications, only the complication with the highest CDG was counted per patient.

Input Feature Definitions All features are measured preoperatively. Recorded baseline variables will include age, gender, maximum aneurysm diameter, anatomical location (artery), total number of aneurysms per patient, if multiple aneurysms were treated during the index session, calcification of the aneurysm wall or neck, aneurysm morphology (saccular, dissecting, fusiform, or other), involvement of critical perforating or branch vessels, and intraluminal thrombosis.

In addition, the investigators will capture prior SAH, mRS at admission, prior aneurysm treatment, presence of anticoagulation/antiplatelet therapy preoperatively, and hypertension, as well as American Society of Anesthesiologists (ASA) grading, the PHASES, ELAPSS, and UIATS scores including the UIATS "pro-repair" and "pro-conservative treatment" subscores. The unruptured intracranial aneurysm treatment score (UIATS) consists of two subscores: One that represents the strength of recommendation for invasive repair of an unruptured aneurysm, and one that represents the strength of recommendation for conservative management of an unruptured aneurysm. The final overall UIATS score is subsequently calculated as the difference between the two subscores. Also included was the surgical approach: minimally invasive or standard approach, and whether a bypass was performed.

02

Conditions studied

  • Aneurysm, Brain

Keywords

  • machine learning
  • unruptured aneurysm
03

In context

Intracranial Aneurysm

427 studies on the registry are indexed under Intracranial Aneurysm; 115 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 200 across 198 observational studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.

Inclusion criteria

  • Adult patients (18 or older)
  • Undergone microsurgical treatment for unruptured intracranial aneurysm
  • Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus.
  • Treated from January 1st 2010 onwards

Exclusion criteria

Exclusion Criteria:

  • No specific exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with unruptured brain aneurysms

    We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study. No intervention.

    Procedure: Microsurgery

Interventions

  • ProcedureMicrosurgery

    Microsurgery for unruptured intracranial aneurysm

06

What researchers measure

Primary outcomes

  1. modified Rankin Scale

    Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. The scale runs from 0 to 5, and higher scores mean a worse outcome.

    Time frame: Within 24 hours of admission to discharge, assessed up to 30 days

  2. Sensorimotor neurological deficits

    Any new sensorimotor neurological deficits after surgery will be captured.

    Time frame: Within 24 hours of admission to discharge, assessed up to 30 days

  3. Clavien Dindo Complication Grading

    Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0. The CDG runs from 0 to 5, and higher scores mean a worse complication.

    Time frame: Within 24 hours of admission to discharge, assessed up to 30 days

07

Study locations

1 of 37 sites recruiting
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
    • Michael Lawton · Contact
    Not yet recruiting
  • UCLA
    Los Angeles, California 90095, United States
    • Linda Liau · Contact
    Not yet recruiting
  • UCSF
    San Francisco, California 94143, United States
    • Mitchel S Berger · Contact
    Not yet recruiting
  • Stanford University
    Stanford, California 94305, United States
    • Gary K Steinberg · Contact
    Not yet recruiting
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    • Daniel Barrow · Contact
    Not yet recruiting
  • University of Illinois
    Chicago, Illinois 60612, United States
    • Fady Charbel · Contact
    Not yet recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    • Antonio Chiocca · Contact
    Not yet recruiting
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
    • Giuseppe Lanzino · Contact
    Not yet recruiting
  • North Shore University Hospital
    Manhasset, New York 11030, United States
    • Amir Dehdashti · Contact
    Not yet recruiting
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
    • Mustafa K Baskaya · Contact
    Not yet recruiting
  • Royal Melbourne Hospital
    Melbourne, Australia
    • Kate Drummond · Contact
    Not yet recruiting
  • Macquarie University
    Sydney, Australia
    • Antonio Di Ieva · Contact
    Not yet recruiting
  • Innsbruck University
    Innsbruck, Austria
    • Claudius Thomé · Contact
    Not yet recruiting
  • Linz Kepler Klinikum
    Linz, Austria
    • Andreas Gruber · Contact
    Not yet recruiting
  • Prague University
    Praha, Czechia
    • Vladimir Benes · Contact
    Not yet recruiting
  • Charité Univesitätsmedizin
    Berlin, Germany
    • Peter Vajkoczy · Contact
    Not yet recruiting
  • Dresden Uniklinikum
    Dresden, Germany
    • Gabriele Schackert · Contact
    Not yet recruiting
  • Düsseldorf Universitätsmedizin
    Düsseldorf, Germany
    • Daniel Hänggi · Contact
    Not yet recruiting
  • Frankfurt University
    Frankfurt, Germany
    • Volker Seifert · Contact
    Not yet recruiting
  • Universitätsmedizin Göttingen
    Göttingen, Germany
    • Veit Rohde · Contact
    Not yet recruiting
  • University of Cologne
    Köln, Germany
    • Roland Goldbrunner · Contact
    Not yet recruiting
  • Unimedizin Mainz
    Mainz, Germany
    • Florian Ringel · Contact
    Not yet recruiting
  • University of Florence - Careggi
    Florence, Italy
    • Alessandro Della Puppa · Contact
    Not yet recruiting
  • University of Genoa
    Genoa, Italy
    • Gianluigi Zona · Contact
    Not yet recruiting
  • University of Messina
    Messina, Italy
    • Antonino Germano · Contact
    Not yet recruiting
  • Carlo Besta
    Milan, Italy
    • Paolo Ferroli · Contact
    Not yet recruiting
  • Padova University
    Padova, Italy
    • Domenico D'Avella · Contact
    Not yet recruiting
  • Gemelli University Hospital
    Roma, Italy
    • Alessandro Olivi · Contact
    Not yet recruiting
  • Sapienza University
    Roma, Italy
    • Antonio Santoro · Contact
    Not yet recruiting
  • University of Verona
    Verona, Italy
    • Giampietro Pinna · Contact
    Not yet recruiting
  • Amsterdam UMC
    Amsterdam, Netherlands
    • W. Peter Vandertop · Contact
    Not yet recruiting
  • Leiden University
    Leiden, Netherlands
    • Wilco C Peul · Contact
    Not yet recruiting
  • UMC Utrecht
    Utrecht, Netherlands
    • Albert van der Zwan · Contact
    Not yet recruiting
  • Burdenko Hospital
    Moscow, Russian Federation
    • Eliava Shalva · Contact
    Not yet recruiting
  • Sahlgrenska Hospital
    Göteborg, Sweden
    • Asgeir Jakola · Contact
    Not yet recruiting
  • Inselspital Bern
    Bern, Switzerland
    • Andreas Raabe · Contact
    Not yet recruiting
  • University Hospital Zurich
    Zürich, Switzerland
    • Victor Staartjes · Contact
    • Giuseppe Esposito · Contact
    Recruiting
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 26, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04819074
Lead sponsor
University of Zurich
Collaborators
Macquarie University, Australia, University of Melbourne, Kepler University Hospital, Medical University Innsbruck, General University Hospital, Prague, Universitätsklinikum Köln, Goethe University, University Medical Center Mainz, University of Göttingen, University Hospital Dresden, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, University of Roma La Sapienza, University of Padova, University of Florence, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, University of Messina, Universita di Verona, Uniuversity of Genua, Italy, Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), UMC Utrecht, Burdenko Neurosurgery Institute, Sahlgrenska University Hospital, University of Bern, Barrow Neurological Institute, Stanford University, Emory University, University of Wisconsin, Madison, University of California, San Francisco, University of Illinois at Chicago, Brigham and Women's Hospital, Mayo Clinic, University of California, Los Angeles, Endeavor Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
May 20, 2021
Primary completion
Jan 1, 2022 (estimated)
Completion
Oct 1, 2022 (estimated)
Last update
Dec 21, 2021

Study contacts

Victor Staartjes
Contact
praemium@usz.ch
+41 44 255 2660
Victor Staartjes
principal investigator · USZ
Giuseppe Esposito
principal investigator · USZ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion